Author

Marie Dupuy

Observed name: M. Dupuy

Institutions: Inserm, Sorbonne Université, Centre Hospitalier Universitaire de Montpellier, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Hôpital Saint Eloi

Observed institutions: Centre National de la Recherche Scientifique, Université Toulouse III - Paul Sabatier, Inserm, Université de Montpellier, Sorbonne Université, Centre Hospitalier Universitaire de Montpellier, Assistance Publique – Hôpitaux de Paris, Institut de Génétique Moléculaire de Montpellier, Pitié-Salpêtrière Hospital, Laboratoire Epidémiologie et Analyses en Santé Publique : Risques, Maladies Chroniques et Handicaps, Hôpital Lapeyronie, Hôpital Saint Eloi

ORCID: 0009-0005-9791-7484

Observed ORCID: 0009-0005-9791-7484

OpenAlex ID: A5041672297

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

2018 · Lorenza Rimassa, Eric Assenat, et al. · The Lancet Oncology · 351

Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes

2019 · Corinne Frere, Barbara Bournet, et al. · Gastroenterology · 91

PDF

Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study

2022 · Morgan Michalet, Karl Bordeau, et al. · Frontiers in Oncology · 40

PDF

Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first‐line treatment in patients with metastatic pancreatic adenocarcinoma ( GATE 1)

2020 · Eric Assenat, Laurent Mineur, et al. · International Journal of Cancer · 38

PDF

Machine Learning‐Assisted Evaluation of Circulating DNA Quantitative Analysis for Cancer Screening

2020 · Rita Tanos, Guillaume Tosato, et al. · Advanced Science · 37

PDF

The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients

2019 · Benoit You, Frédéric Mercier, et al. · EBioMedicine · 21

PDF

Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM

2024 · Lina Hountondji, Stéphanie Faure, et al. · Alimentary Pharmacology & Therapeutics · 19

PDF

Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study

2023 · Karl Bordeau, Morgan Michalet, et al. · Journal of Clinical Medicine · 17

PDF

Survival after Multimodal Treatment Including Surgery for Metastatic Esophageal Cancer: A Systematic Review

2022 · Thomas Bardol, Lorenzo Ferre, et al. · Cancers · 14

PDF

Plasma hPG80 (Circulating Progastrin) as a Novel Prognostic Biomarker for Hepatocellular Carcinoma

2022 · Marie Dupuy, Sarah Iltache, et al. · Cancers · 13

PDF

Sequential treatment with Nab-paclitaxel plus Gemcitabine and Folfirinox in metastatic pancreatic adenocarcinoma: GABRINOX phase II results.

2018 · Eric Assenat, Christelle De La Fouchardiere, et al. · Journal of Clinical Oncology · 11

Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study

2024 · Rémy Nicolle, Cindy Canivet, et al. · EBioMedicine · 8

Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients

2019 · Regis Souche, Antoine Coignac, et al. · Clinics and Research in Hepatology and Gastroenterology · 8

PDF

Modelling hepatocellular carcinoma microenvironment phenotype to evaluate drug efficacy

2025 · Sara Cherradi, Salomé Roux, et al. · Scientific Reports · 5

PDF

Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy

2019 · Thibault Mazard, Eric Assenat, et al. · Digestive and Liver Disease · 4

PDF

Multimodal treatment including surgery for esophageal adenocarcinoma with liver oligo-metastases: a pathological complete response but early brain metastasis

2020 · Regis Souche, Marie Dupuy, et al. · Clinical Journal of Gastroenterology · 3

Early Encephalic Toxicity after Inadvertent Intrathecal Injection of Low Osmolar Contrast Medium

2012 · L. Lonjaret, T. Geeraerts, et al. · The Neuroradiology Journal · 3

Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study

2025 · E. Alouani, C. Canivet, et al. · ESMO Gastrointestinal Oncology · 2

PDF

Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by folfirinox in metastatic pancreatic adenocarcinoma

2016 · E. Assenat, Cdela Fouchardiere, et al. · Annals of Oncology · 1

Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer.

2016 · Laetitia Mais, Héloise Bourien, et al. · Journal of Clinical Oncology · 1

Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in metastatic pancreatic adenocarcinoma.

2016 · Eric Assenat, Christelle De La Fouchardiere, et al. · Journal of Clinical Oncology · 1

Incidence and determinants of non-radial vascular approach for coronary angiography in heart transplant recipients

2026 · Niki Procopi, Paul Guedeney, et al. · Archives of cardiovascular diseases

SAT-068 Long-term outcomes following checkpoint inhibitor-induced liver injury

2026 · Kenza Faouzi, Alexandre Maria, et al. · Journal of Hepatology

SAT-076 Impact of liver biopsy on causality assessment in checkpoint inhibitor–induced liver injury

2026 · Lucy Meunier, Alexandre Maria, et al. · Journal of Hepatology

A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma

2026 · Sara Cherradi, Salomé Roux, et al. · Translational Oncology

Works count: 33

Citation count: 688

H-index: 11

I10-index: 11